Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
KN-93 Phosphate (KN 93; KN93), the phosphate salt of KN-93, is a potent, cell-permeable and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with potential anti-Parkinson's disease and anticancer activity. It inhibits CaMKII with a Ki of 0.37 μM, and showed no effects on APK, PKC, MLCK or Ca2+-PDE activities. KN-93 suppresses ventricular arrhythmia induced by LQT2 without decreasing TDR. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. KN-93 protects rat cerebral cortical neurons from N-methyl-D-aspartic acid-induced injury.
ln Vitro |
Ninety-five percent of the cells were in the G1 phase after two days of treatment with KN-93 phosphate. G1 arrest is reversible, and cells peak into the S and G2-M phases one day after KN-93 phosphate is released. KN-93 phosphate also inhibits the proliferation of NIH 3T3 fibroblasts when they are stimulated by platelet-derived growth factor-BB, epidermal growth factor, and basic fibroblast growth factor [1]. While KN-93 phosphate strongly dissipates the proton gradient produced in stomach membrane vesicles and decreases cavity volume, it also inhibits the action of H+ and K+-ATPase [2]. Preventing LV developmental stress rises during action potential extension and early afterdepolarization is possible with KN-93 phosphate (0.5 μM). Early afterdepolarization is characterized by a rise in Ca2+-independent CaM kinase activity, which is inhibited by KN-93 phosphate [3].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Biochem Biophys Res Commun.1991 Dec 31;181(3):968-75;Neuropsychiatr Dis Treat.2013;9:1213-20.
|
Molecular Formula |
C26H32CLN2O8PS
|
|
---|---|---|
Molecular Weight |
599.03
|
|
CAS # |
1188890-41-6
|
|
Related CAS # |
KN-93;139298-40-1;KN-93 hydrochloride;1956426-56-4
|
|
SMILES |
CN(C/C=C/C1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC.OP(=O)(O)O
|
|
Chemical Name |
(E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide phosphate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6694 mL | 8.3468 mL | 16.6937 mL | |
5 mM | 0.3339 mL | 1.6694 mL | 3.3387 mL | |
10 mM | 0.1669 mL | 0.8347 mL | 1.6694 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.